Melio

Santa Clara, United States Founded: 2018 • Age: 8 yrs
Blood-based pathogen detection devices are manufactured for healthcare applications.

About Melio

Melio is a Healthcare company based in Santa Clara (United States) founded in 2018 by Shelley Lawrence, Stephanie Fraley, and Mridu Sinha. Blood-based pathogen detection devices are manufactured for healthcare applications. It operates on a HealthTech model. Melio has raised $4.25 million across 3 funding rounds from investors including IndieBio and LongeVC. Its chief executive, as recorded, is Mridu Sinha. Melio offers products and services including Melio Diagnostic Platform. Its focus areas include Medical Devices and Diagnostic Equipment. Its legal entity is Melio, Inc.

Company details

A culture-free, rapid, and comprehensive blood testing platform is developed by Melio to identify pathogens in hours instead of days. Focus is placed on critical applications such as newborn care in NICUs, where timely diagnosis is essential. Advanced systems engineering, microfluidics, and machine learning are integrated to ensure faster and precise treatments. The technology is designed to adapt and detect newly emerging pathogens, expanding its diagnostic database. Solutions are aimed at addressing global challenges like antibiotic resistance within the healthcare sector.

  • Headquarters Santa Clara, United States
  • Founders Shelley Lawrence, Stephanie Fraley, Mridu Sinha
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website melio.tech
  • Social LinkedIn
  • Legal Name Melio, Inc.
Key Metrics
  • Total Equity Funding
    $4.25M (USD)

    in 3 rounds

  • Latest Funding Round
    $4M (USD), Series A

    Jun 2024

  • Investors
    IndieBio

    & 1 more

Products & Services of Melio

Melio offers a comprehensive portfolio of products and services, including Melio Diagnostic Platform.

Melio Diagnostic Platform
Medical Technology

Bloodborne pathogen testing is delivered rapidly and accurately.

Funding Insights of Melio

Melio has successfully raised a total of $4.25M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $4 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $4.25M
  • Total Rounds 3
  • Last Round Series A β€” $4M
  • First Round $250,000

    (Dec 2022)

  • Investors Count 2

All 3 funding rounds of Melio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2024$4MSeries A––
–
May 2023Seed–LongeVC
–
Dec 2022$250,000Seed–IndieBio
–
Valuation history

2 investors in total: 2 institutional.

Investors in Melio

Melio has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include IndieBio and LongeVC.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Biotech startups are accelerated through IndieBio's focused programs.
indiebio.coSan Francisco, United States
LongeVC is focused on venture capital investments in biotech.
longevc.com
Premium access

Investor details for Melio

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Melio

20 people are tracked at Melio (8 in leadership, 9 in board & advisors, 3 in team).

NameRoleGroup
Shelley Lawrence
Co-FounderLeadership
Stephanie Fraley
Co-FounderLeadership
Mridu Sinha
Founder & CEOLeadership
Evan Foster
Director, Systems Architecture And IntegrationLeadership
Luc Bousse
Senior Director Of Microfluidics And Systems IntegrationLeadership
Artem Trotsyuk
Head of Business AffairsLeadership
Todd Peterson
Head of Product DevelopmentLeadership
Clare Fasching
Director Assay DevelopmentLeadership
Ryan Simkovsky
Scientific AdvisorBoard & advisors
Claude Benchimol
Business AdvisorBoard & advisors
Todd Coleman
Scientific AdvisorBoard & advisors
Daniel Schmitigal
Business AdvisorBoard & advisors
Ravi Jain
AdvisorBoard & advisors
Anula Jayasuriya
AdvisorBoard & advisors
Ramon Felciano
AdvisorBoard & advisors
Ravi Mistry
AdvisorBoard & advisors
Shrabani Jain
AdvisorBoard & advisors
Saurabh Mehta
Full Stack DeveloperTeam
Himanshu Chittora
Full Stack ML EngineerTeam
Julia Wellons
Research AssociateTeam
Premium access

Complete people profiles for Melio

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Melio

3 dated milestones of Melio across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded Melio is founded.
  2. Funding First funding round of $250K.
  3. Funding Latest funding round, Series A, of $4.0M.

Web traffic of Melio

The website of Melio (melio.tech) receives about 3.5K visits a month.

  • Monthly visits
    3.5K

    ▲ 26.9% vs previous month

Top companies in Traditional Diagnostics & Medical Devices

3 companies that operate in the same segment as Melio (Traditional Diagnostics & Medical Devices) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Materials management solutions are provided for healthcare organizations.
1892Chicago, Illinois, United StatesUSD 29.13 MUSD 20.63 B53,000
3D-printed orthopedic products are manufactured for medical applications.
1941Kalamazoo, Michigan, United States
Ophthalmic pharmaceuticals and instruments are developed for eye care.
1853Bridgewater, New Jersey, United StatesUSD 5.1 B13,500
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Melio

Melio was founded in 2018 and raised its 1st funding round 4 years after it was founded.

Melio is headquartered in Santa Clara, United States. It is registered at Santa Clara, California, United States.

Mridu Sinha is the CEO of Melio, as recorded in our data. They have also founded this company.

Melio is a funded company, having raised a total of $4.25M across 3 funding rounds to date. The company's 1st funding round was a Seed of $250K, raised on Dec 2022.

A culture-free, rapid, and comprehensive blood testing platform is developed by Melio to identify pathogens in hours instead of days. Focus is placed on critical applications such as newborn care in NICUs, where timely diagnosis is essential. Advanced systems engineering, microfluidics, and machine learning are integrated to ensure faster and precise treatments. The technology is designed to adapt and detect newly emerging pathogens, expanding its diagnostic database. Solutions are aimed at addressing global challenges like antibiotic resistance within the healthcare sector.

Melio offers Melio Diagnostic Platform.

Melio has 2 investors. Key investors include IndieBio, and LongeVC.

Melio operates through Melio, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available